Coherus Oncology Q3 2026 net loss from continuing operations narrows 13% year over year to $38.9 million

• Coherus Oncology’s third-quarter 2026 net loss from continuing operations narrowed 13% year over year to $38.9 million.
• Net revenue from continuing operations rose 23% year over year to $14.3 million, primarily driven by LOQTORZI volume growth.
• The strategic prioritization plan focuses tagmokitug/toripalimab development on esophageal cancer and reduces headcount by about 30%.
• Management expects quarterly core cash burn savings of $6 million–$7 million, lowering LOQTORZI revenue needed to cover it to $25 million–$30 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-124511), on November 09, 2026, and is solely responsible for the information contained therein.